Piper Sandler Initiates Coverage On Tourmaline Bio with Overweight Rating, Announces Price Target of $65
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi has initiated coverage on Tourmaline Bio (NASDAQ:TRML) with an Overweight rating and a price target of $65.
October 25, 2023 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Tourmaline Bio with an Overweight rating and a price target of $65, which could positively impact the stock.
Analyst ratings and price targets can significantly influence a stock's performance. An Overweight rating suggests that the analyst believes the stock will outperform its industry in the near term. The price target of $65 indicates the analyst's confidence in the stock's potential upside. This news is likely to be viewed positively by investors, potentially leading to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100